deferasirox

Known as: deferasirox [Chemical/Ingredient], 4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid, 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid 
A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Cardiac iron overload causes most deaths in beta-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
UNLABELLED Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in addition to baseline body… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVES/METHODS This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in regularly transfused patients… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated… (More)
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND AND OBJECTIVES Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?
Review
2006
Review
2006
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?